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Abstract
The presence of the extracellular matrix (ECM) proteins collagen types I and IV, laminin and fibronectin on the
surface of HEp-2 cells was confirmed by flow cytometry using monoclonal antibodies. Monoclonal antibodies
directed against these ECM proteins reduced the adherence of C. albicans ATCC 44990 to HEp-2 cells, the
greatest reductions being evident in assays which incorporated anti-collagen type IV monoclonal antibody. The
ability of sugaramines to inhibit the adherence of C. albicans to a variety of cell types has been demonstrated
previously and the most significant reduction in C. albicans – HEp-2 adherence was in assays which incorporated
0.2M galactosamine. The combination of anti-collagen IV monoclonal antibody and galactosamine reduced the
adherence of C. albicans to HEp-2 cells by approximately 70% (p < 0.05).
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Abbreviations: ECM: Extracellular matrix, MAb(s): Monoclonal antibody (antibodies), PBS: Phosphate buffered
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Introduction
The dimorphic yeast Candida albicans is an oppor-
tunistic fungal pathogen of humans and is capable of
inducing a range of superficial and systemic diseases
in the immunocompromised host [1]. A number of vir-
ulence factors enable the yeast to colonise the host and
these include the ability to adhere to a range of tissues,
to undergo phenotypic switching and to produce extra-
cellular enzymes such as phospholipases and proteases
[2]. Adherence of C. albicans to host tissue is con-
sidered to be crucial to the success of the pathogenic
process and appears to be a prerequisite to colonisation
and subsequent infection [3, 4]. Adherence is achieved
by a combination of specific and non-specific mecha-
nisms. Specific mechanisms involve the ability of the
yeast to recognise a variety of host cell receptors using
cell surface adhesins [5]. Non-specific mechanisms
include electrostatic forces, aggregation and cell sur-
face hydrophobicity [6, 7]. While it is clear that the
latter forces are involved in adherence, their overall
contribution appears to be less than that of the specific
mechanisms [8].
A number of proteins associated with the extra-
cellular matrix (ECM) of epithelial and endothelial
cells have been implicated as possible targets for C.
albicans adherence [9, 10]. These include fibronectin,
located in the interstitium of the ECM, collagen types
I and IV found in the interstitium and basement mem-
brane of the ECM and laminin which is also located in
the basement membrane [10]. Proteins on the surface
of C. albicans mediate adherence to these molecules
and are classified as integrin analogues due to their
structural and functional homology to mammalian
integrins [11–13].
Partial inhibition of adherence of C. albicans to
buccal mucosal cells and corneocytes [15], an oe-
sophageal cell line [16] and vaginal epithelial cells
[17] has been achieved using sugaramines. This inhi-
bition appears to result from a reversible interaction
of the sugaramine with the fungal cell wall preventing
direct contact between the fungal cell and the target
surface [15].
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The aim of the work presented here was to estab-
lish whether the ECM proteins laminin, fibronectin
and collagen types I and IV were expressed on the
surface of HEp-2 cells and to establish the ability of
MAbs directed against these proteins to block the ad-
herence of C. albicans to HEp-2 cells. The role of
MAbs, directed against ECM proteins, in combina-
tion with sugaramines in altering the adherence of C.
albicans to HEp-2 cells was also investigated.
Materials and Methods
Yeast strain and culture conditions
C. albicans ATCC 44990 was used throughout this
study. Stationary phase cultures (5 × 108/ml) of C.
albicanswere obtained by growing cells in YEPD (2%
(w/v) glucose (Sigma Chemical Co. Ltd., Dorset, Eng-
land), 2% (w/v) Bactopeptone (Difco Laboratories,
Michigan, USA), 1% (w/v) Yeast extract (Oxoid Ltd.,
Basingstoke, England) overnight at 30 ◦C and 200 rpm
in an orbital incubator.
Cell culture.
The HEp-2 cell line (ATCC CCL23, derived from
an epidermoid carcinoma of the larynx [18]) was
obtained from the American Type Culture Collec-
tion (Maryland, USA) and was cultured in MEM
(Sigma) supplementedwith 5% (v/v) Foetal calf serum
(GIBCO Laboratories, Paisley, Scotland) and 4mM
L-glutamine (GIBCO). Cells were grown in tissue cul-
ture flasks (Nunc, Roskilde, Denmark) at 37 ◦C and
5% CO2 in a humidified atmosphere and subcultured
by trypsinisation every 3–4 days.
Monoclonal Antibodies
Commercially available MAbs were used to detect
the presence of four ECM proteins. Monoclonal anti-
fibronectin (Sigma) recognises an epitope located
within the fifth type III repeat of human plasma fi-
bronectin and is common to all fibronectin forms.
Monoclonal anti-laminin (Sigma) has an affinity for
the basal membranes of human, pig and cat cells but
not those of rabbit, mouse or dog. Monoclonal anti-
collagen type I antibody (Sigma) recognises the native
form of collagen type I and shows no crossreactivity
with other collagens such as collagen II, III, IV and V.
Monoclonal anti-collagen type IV (Sigma) recognises
epitopes located on the alpha 1 and 2 chains of human
collagen type IV.
Binding of monoclonal antibodies to HEp-2 cells
Sub-confluent HEp-2 cells were harvested using a cell
scraper (Nunc), washed and resuspended in PBS con-
taining the MAbs directed against the ECM proteins.
The anti-fibronectin MAb was used at a dilution of
1/100 in PBS while the other three MAbs were used
at dilution of 1/200. Cells were incubated at 4 ◦C for
1 hr at 175 rpm in an orbital incubator to facilitate
the binding of the MAbs to the ECM proteins [21].
Subsequently, cells were centrifuged at 1000 rpm for
5 mins, washed twice and resuspended in PBS.
Flow cytometry
Hep-2 cells, previously incubated in the presence of
the anti-ECM protein MAbs, were resuspended in 1ml
PBS containing anti-mouse IgG (Fab specific) FITC
conjugate (Sigma) and incubated at 4 ◦C for 1 hour
at 175 rpm. Cells were harvested by centrifugation,
washed with PBS, resuspended in 1ml of FACSflow
(Becton Dickinson, San Jose, California, USA) and
analysed by flow cytometry on a FACScan (Becton
Dickinson) using Lysis II software. In each case the
fluorescence of 10,000 cells was analysed.
Adherence assay
Stationary phase cultures of C. albicans ATCC 44990
were harvested by centrifugation, washed and re-
suspended in PBS. Sub-confluent HEp-2 cells were
harvested using a cell scraper (Nunc), centrifuged,
washed and resuspended in PBS. Yeast and HEp-2
cells were mixed in a ratio of 50:1 (5 × 107: 1 ×
105) in a final volume of 2 mls and incubated at 37 ◦C
for 2 hrs. This mixture was subsequently smeared
onto glass slides and allowed to air dry before being
heat fixed and stained with a 1% (w/v) crystal vio-
let solution. The number of yeast adhering to each of
200 HEp-2 cells was determined microscopically per
treatment.
Inhibition assays
The effect of the four anti-ECM MAbs on the adher-
ence of C. albicans to HEp-2 cells was determined by
first binding the antibodies to the cells as described.
Cells were then harvested, washed twice and resus-
pended in PBS. Yeast cells were added directly to this
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cell suspension in a ratio of 50:1 and adherence was
measured after 2 hours as described.
The inhibitory action of sugaramines was assessed
by incubating yeasts and HEp-2 cells in PBS contain-
ing either 0.02 or 0.2 M galactosamine (Sigma) or
mannosamine (Sigma). In the series of experiments
which investigated the combination of anti-ECM pro-
tein MAb and sugaramine, cells were first treated with
the MAb as described. Cells were subsequently har-
vested, washed and resuspended in PBS containing the
stated concentration of sugaramine in the presence of
C. albicans. Adherence was measured as described.
The percentage inhibition of adherence was calcu-
lated using the following formula:
% Inhibition = (1 − (A/B)) × 100
Where A is the mean number of yeasts adhering
to treated cells and B is the mean number of yeasts
adhering to untreated cells.
Statistical analysis
The mean number of yeasts adhering to each of 200
HEp-2 cells was enumerated per treatment. Adherence
assays were performed in duplicate on three separate
occasions. Statistical analysis was performed using a
Sigma Stat package (Sigma) with the Kruskial-Wallis
Test and the Dunns Test being employed to establish
the existence of a significant difference (p < 0.05)
between the treatments and control.
Results
Assays were performed to determine whether the
ECM proteins collagen types I and IV, laminin and fi-
bronectinwere expressed on the surface of HEp-2 cells
with a view to establishing their relative importance
in mediating yeast-HEp-2 adherence. Sub-confluent
HEp-2 cells were exposed to each of the four MAbs
as described. An anti-mouse IgG FITC conjugate was
subsequently bound to the attached MAbs and the flu-
orescence of the cells was analysed by flow cytometry.
FACS analysis (Figure 1) indicated the presence of
fibronectin, collagen types I and IV and laminin on
the surface of HEp-2 cells. The relative levels of flu-
orescence due to the anti-laminin, anti-fibronectin and
anti-collagen I MAb-FITC complexes appeared sim-
ilar while that due to the anti-collagen IV MAb was
higher implying a greater abundance of collagen IV
on the cell surface.
Figure 1. FITC fluorescence of HEp-2 cells treated with anti-ECM
protein monoclonal antibodies.
HEp-2 cells were labelled with anti-ECM protein MAbs and ex-
posed to the FITC conjugate. The fluorescence of ten thousand cells
was analysed by flow cytometry using a Becton Dickinson FACScan
with Lysis II software. The control represents the fluorescence due
to the FITC conjugate binding to untreated HEp-2 cells.
Once the presence of the four ECM proteins on
the surface of the HEp-2 cells was established, assays
were performed to investigate whether MAbs directed
against these could affect the adherence of C. albi-
cans. The adherence of C. albicans to HEp-2 cells
with boundMAbs was determined as described.When
compared to the control, those HEp-2 cells with bound
MAbs manifested reduced levels of yeast adherence
(Figure 2) with reductions in adherence varying be-
tween 35 and 50% depending on the antibody. The
greatest reduction in adherence was consistently ob-
served when anti-collagen type IV MAb was used
(typically in the order of 50% (p< 0.05)).
The inhibitory effect of sugaramines on the adher-
ence of C. albicans to HEp-2 cells was determined.
In all cases C. albicans and HEp-2 cells were incu-
bated in 2 mls of PBS containing either 0.02 M or
0.2 M galactosamine or mannosamine [15]. The data
obtained here (Figure 3) indicate that the inhibition
of adherence was concentration dependent, with the
greatest reductions being observed when the yeast-
HEp-2 mixture was incubated in the presence of either
0.2 M galactosamine or mannosamine.
Significant reductions in the adherence of C. al-
bicans to HEp-2 cells are achievable using either a
MAb (particularly the anti-collagen type IV mono-
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Figure 2. Inhibition of adherence of Candida albicans to HEp-2
cells which had been labelled with selected monoclonal antibodies.
HEp-2 cells were labelled with selected MAbs and incubated with
C. albicans ATCC 44990 in adherence assays as described. Val-
ues represent the mean±SE percentage inhibition of adherence
(∗ indicates a significant difference (p < 0.05) compared to the
control.)
clonal antibody) directed against an ECM protein or
a sugaramine. Assays to establish the potential of
combining both of these strategies were performed.
HEp-2 cells previously labelled with the MAb di-
rected against anti-collagen type IV were mixed with
yeast cells in PBS containing 0.2M galactosamine and
adherence was measure as described.
Reductions in C. albicans adherence due to the
presence of anti-collagen type IV MAb on the surface
of the HEp-2 cells were approximately 55% (p< 0.05)
(Figure 4). The presence of galactosamine (0.2M)
in adherence assays produced a similar sized reduc-
tion in adherence. The co-incubation of HEp-2 cells,
pre-labelled with anti-collagen type IV MAb, and C.
albicans in PBS containing 0.2 M galactosamine gave
a reduction of approximately 70% (p < 0.05) in the
overall adherence level.
Figure 3. Adherence of Candida albicans to HEp-2 cells in the
presence of sugaramines.
HEp-2 cells were harvested and incubated with cells ofC. albicans
ATCC 44990 in the presence of 0.02 or 0.2 M galactosamine or
mannosamine. Values represent the mean percentage inhibition of
adherence ± SE of the mean (∗ indicates a significant difference (p
< 0.05) compared to the control.)
Discussion
The adherence of C. albicans to host tissue is achieved
by a combination of specific and non-specific interac-
tions [21]. The specific adherencemechanisms include
interactions with the proteins of the ECM such as
collagen types I and IV, laminin and fibronectin [9,
10]. C. albicans has an affinity for fibronectin [20]
and immobilised collagen type IV [10]. A fibronectin
adhesin has been characterised for C. albicans [11]
and laminin adhesins are present on the surface of C.
albicans germ tubes [6, 21]. Results presented here
suggest that all of these proteins, particularly colla-
gen IV, are involved in facilitating the adherence of
C. albicans to HEp-2 cells and their presence on the
surface of HEp-2 cells was confirmed by flow cytom-
etry. MAb labelled HEp-2 cells demonstrated reduced
susceptibility to yeast adherence and the greatest in-
hibition of adherence was evident when anti-collagen
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Figure 4. Adherence of Candida albicans to HEp-2 cells labelled
with anti-collagen IV monoclonal antibody and in the presence of
0.2 M galactosamine.
Anti-collagen type IV MAb labelled HEp-2 cells were incubated
with cells of C. albicans ATCC 44990 in the presence of 0.2 M
galactosamine. Values represent the mean percentage inhibition of
adherence ± SE of the mean. (∗ indicates a significant difference (p
< 0.05) compared to the control.)
type IV MAb was used. This correlates with the pres-
ence of collagen type IV on the surface of HEp-2 cells
as indicated by flow cytometry. Since the MAbs em-
ployed here were not directed specifically against the
receptors for C. albicans the reductions in adherence
may result from stearic hindrance rather the direct
disruption of the receptor – adhesin interactions.
The inhibition of adherence of C. albicans to a
variety of cell types in the presence of sugaramines
has been demonstrated previously [15–17] and results
from a reversible interaction of the sugaramine with
the fungal cell wall preventing close contact occurring
between the yeast cell and the epithelial cell surface
[15]. A similar inhibition of adherence of C. albi-
cans ATCC 44990 to HEp-2 cells was observed here
with reductions occurring in a concentration depen-
dent manner. Reductions in the order of 65% in C.
albicans adherence to HEp-2 cells were observed in
assays where the yeast and HEp-2 cells were incu-
bated in the presence of either 0.2M galactosamine or
mannosamine. Reductions of a similar magnitude in
the adherence of C. albicans to corneocytes and buc-
cal mucosa cells have previously been reported using
sugaramines at the same concentrations as employed
here [15].
The use of HEp-2 cells labelled with anti-collagen
type IV MAb in assays incorporating 0.2M galac-
tosamine reduced the adherence of C. albicans to
HEp-2 cells by approximately 70% (p < 0.05) (Fig-
ure 4). This indicates that the reduction in adherence
evident when a MAb directed against a target ECM
protein can be augmented by performing the assay in
the presence of a sugaramine. The anti-collagen IV
MAb reduces adherence by indirectly disrupting the
interaction of the yeast adhesin with one of the ECM
proteins implicated as a target for yeast adherence
while the sugaramine prevents close contact occurring
between the cell types [15].
Previous work has demonstrated that HEp-2 cells
constitute a good model for studying the interaction of
C. albicans with cultured epithelial cells [14]. Cul-
tured cells have been used extensively to study the
adherence of C. albicans [18, 20, 21] and represent
homogeneous populations of viable cells, the surfaces
of which have not been subjected to bacterial or enzy-
matic modification as occurs with buccal and vaginal
epithelial cells [1]. The work presented here indicates
that a significant reduction in the adherence ofC. albi-
cans to HEp-2 cells is possible using agents which do
not bind specifically to receptor sites but rather act by
indirectly disrupting the yeast adhesin – cell receptor
interaction or by preventing close contact occurring
between the yeast and the epithelial cell.
While HEp-2 cells are a cultured cell line, an ap-
proach such as that described here may have potential
in reducing the adherence of C. albicans to buccal or
vaginal epithelial cells in vitro.
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